Global AI Drug Discovery Research Center Signs MOU with Elsevier N
- Date2025.12.11
- 363
Strategic Partnership Established to Strengthen AI-Based Global Drug Development Capabilities
The Global AI Drug Discovery Research Center at Ewha Womans University (Director: Professor Choi Sun) has signed a Memorandum of Understanding (MOU) with Elsevier, a leading global academic and research information company.
(From left) Professor Choi Sun, Director of the Global AI Drug Discovery Research Center; Mohamed Kamel, President of Life Sciences at Elsevier
Through this agreement, the two institutions plan to strategically collaborate by combining Ewha Womans University’s strengths in AI–bio convergence research with Elsevier’s extensive data infrastructure and AI-driven analytics platforms, accelerating innovation in the global biotechnology and pharmaceutical sectors.
At the signing ceremony held on Tuesday, November 4, at the College of Pharmacy building, Professor Choi stated, “The convergence of AI and biotechnology is a key field that will define the future of drug discovery. This collaboration is highly meaningful as Ewha advances toward becoming a global hub of technological innovation.” She added, “By bringing together the capabilities of both institutions, we aim to generate research outcomes that contribute to human health.”
Mohamed Kamel, President of Life Sciences at Elsevier, remarked, “We deeply resonate with Ewha Womans University’s vision of advancing high-risk, high-reward drug development through AI-driven innovation and sharing research outcomes for the public good. We will continue to provide strong support and collaboration in future research and drug candidate discovery.”
△(Front row, from left)Ryu Jaesang, Associate Dean, College of Pharmacy, Ewha Womans University; Lee Hwajeong, Dean; Professor Choi Sun, Director of the Global AI Drug Discovery Research Center; Mohamed Kamel, President of Life Sciences, Elsevier; Jin Sunhee, Head of Korea, Elsevier; Timur Mazidov, Senior Product Manager, Reaxys
Under the MOU, the two institutions will establish concrete collaboration frameworks in areas including △joint research initiatives △researcher capacity-building programs △exchange of AI-based drug discovery technologies. These efforts are expected to enhance global competitiveness in the bio-pharmaceutical industry while also contributing to the innovative development of Korea’s drug discovery research ecosystem.
Elsevier supports researchers across the entire drug discovery pipeline—from early-stage hit identification and toxicity prediction to clinical candidate selection—through its world-class chemical and biological database Reaxys AI and life sciences and medical database Embase AI. In particular, its predictive analytics, machine learning capabilities, and large-scale data–driven knowledge exploration tools are widely recognized for significantly addressing the high cost and long timelines traditionally associated with drug development.
Established in 2020, the Global AI Drug Discovery Research Center at Ewha Womans University aims to dramatically reduce the time and cost required for research and development (R&D) by leveraging cutting-edge AI technologies, while maximizing efficiency and success rates in drug discovery. Through active multidisciplinary and interdisciplinary research, the center continues to produce globally competitive research outcomes and to build an innovative research ecosystem through international collaboration as well as partnerships among academia, industry, research institutes, and hospitals.